Tom’s of Maine says it will remedy mold, bacteria problems found by FDA at Sanford plant - mainebiz.biz
Tom's of Maine will address mold and bacteria issues identified by the FDA at their Sanford plant.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 9, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. All manufacturers and stakeholders in the pharmaceutical and personal care sectors, particularly those involved with Tom's of Maine products. should confirm how it applies to their specific situation before acting. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed. Regulated niches like Pharmaceutical Manufacturing (FDA/DEA) move faster than most operators can track by hand, which is why Aforeworn watches the official sources for you and flags every material change the moment it appears.
What changed
Tom's of Maine is taking corrective actions to resolve FDA-identified mold and bacteria problems.
Who it affects
All manufacturers and stakeholders in the pharmaceutical and personal care sectors, particularly those involved with Tom's of Maine products.
What you must do
Monitor updates from Tom's of Maine regarding the remediation process and ensure compliance with any new guidelines that may arise.
Deadline
No fixed deadline was published, but changes like this are often enforced quickly — act promptly.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- The FDA let substandard factories ship these medications to the U.S. - michiganadvance.com
- The FTC Challenges Companies’ Allegedly Improper Orange Book Patent Listings - skadden.com
- Alabama Board of Medical Examiners Issues Warning of Non-FDA-Approved Peptides - drugtopics.com
- Psychedelics Policy Newsletter: DEA considers rescheduling psilocybin, FDA releases rejection decision, and more - reason.org
- Novo plant hit with FDA's most serious inspection classification, portending possible delays for partners - fiercepharma.com